Intracellular Signaling Proteins Emerge as a Key Target in Drug Development
A new approach to drug discovery, focusing on the targeted modulation of intracellular signaling proteins, is gaining momentum. Research led by MedUni Vienna highlights this strategy as a means to control disease-relevant signaling pathways and minimize side effects, offering hope for more personalized and effective therapies, particularly in neurological disorders.
Understanding β-Arrestins: Cellular Switching Points
The research, published in the journal Trends in Pharmacological Sciences, centers on β-arrestins – multifunctional proteins that act as switching points in cellular signal transduction. These proteins regulate, amplify, or direct signals within cells, but have historically been underutilized as specific drug targets. However, emerging evidence links alterations in β-arrestins to a variety of diseases, including brain disorders.
Precision Therapies with Tailor-Made Peptides
Christian Gruber, the study leader from the Center for Physiology and Pharmacology at MedUni Vienna, explains that their research demonstrates how specifically designed peptides – small protein molecules created through computational design or derived from chemical libraries – can bind to target structures like receptors or arrestins. This approach offers a more differentiated control of signaling pathways compared to traditional active substances, which often have broader, less specific effects.
Cyclic and nature-inspired peptides, characterized by their ring-shaped structure based on natural blueprints, are particularly promising due to their stability and precise action on defined cellular signaling processes. “In this way, our research expands the toolkit for developing precision therapies that are potentially more effective and better tolerated,” Gruber and his team state.
New Perspectives for Neurological Diseases and Beyond
The targeted modulation of β-arrestins presents new therapeutic avenues for neurological diseases like Alzheimer’s disease and certain tumors, such as glioblastoma. For these applications, peptides must be small, stable, and cyclic to effectively enter cells and, crucially, cross the blood-brain barrier.
Researchers are now focusing on methods to deliver these peptides specifically to their target sites within tissues, maximizing their impact and minimizing off-target effects. This ongoing work aims to refine the precision and efficacy of these novel therapies.
Further Research
The findings are detailed in the publication: Simon Hasinger et al, β-Arrestins and disease-linked variants: opportunities for targeted modulation, Trends in Pharmacological Sciences (2026).
Source: Medical University of Vienna